Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc.

ANAHEIM, CA - (NewMediaWire) - April 04, 2019 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that Joseph J. Galligan has been appointed as senior advisor to the Company.

Mr. Joseph John Galligan, CFA was formally an Executive Vice President and Portfolio Manager at DoubleLine Capital LP, an investment firm with over $100 billion in assets under management, where he was one of the five founding partners. Previously, Mr. Galligan served as Senior Vice President of Apex Mortgage Capital Inc. He was also a Managing Director and Portfolio Manager at The TCW Group, Inc. Mr. Galligan held senior roles at Smith Barney, First Boston, and Scudder Stevens & Clark. He is a Chartered Financial Analyst and holds a B.S. in Economics with a concentration in Finance from the Wharton School of Business at the University of Pennsylvania.

Joe Galligan, Senior Adviser of BioCorRx, commented, “Opioid and alcohol use disorders affect the majority of families in the U.S., either directly or indirectly.  BioCorRx has developed an innovative approach that I believe will help countless Americans in dealing with this epidemic. I am proud to have joined BioCorRx as a senior advisor and look forward to working closely with the senior management team to advance the Company’s pipeline.”

Brady Granier, CEO, President and Director of BioCorRx., stated, “Over the years, Joe has been a major supporter of the Company and we are delighted to have him join the team as a senior advisor. His broad capital markets experience and proven leadership will be invaluable as we prepare to list on NASDAQ and further execute on our growth strategy.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance abuse addiction and related disorders. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com.

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com